^
Association details:
Biomarker:KRAS G12D
Cancer:Colorectal Cancer
Regimen:FOLFOX (5-fluorouracil + leucovorin calcium + oxaliplatin)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX

Published date:
07/16/2021
Excerpt:
In conclusion, the findings of the present study indicate that among three types of KRAS mutations, G12D/V mutations were consistently associated with less TIL infiltration and shorter RFS in two independent cohorts of stage III CRC patients treated with adjuvant FOLFOX.
DOI:
https://doi.org/10.1038/s41598-021-94044-4